Simple pharmacological perturbation of reciprocal nodes (e.g., IGF1R, AXL, AKT, etc.)in existing PDA GEMMs will in principle affect all cell types (e.g., tumor cells, PSCs, immune cells) and cannot provide axis-specific information in vivo. The gene discussed is AXL; the disease is Patent ductus arteriosus.